上海医药
上海醫藥
상해의약
SHANGHAI MEDICAL & PHARMACEUTICAL JOURNAL
2015年
11期
29-32
,共4页
李荣%区腾飞%巫碧佳%李永鸿
李榮%區騰飛%巫碧佳%李永鴻
리영%구등비%무벽가%리영홍
阿托伐他汀%阿司匹林%脑梗死%疗效%不良反应
阿託伐他汀%阿司匹林%腦梗死%療效%不良反應
아탁벌타정%아사필림%뇌경사%료효%불량반응
atorvastatin%aspirin%cerebral infarction%efifcacy%adverse reaction
目的：探讨不同剂量阿托伐他汀联合阿司匹林治疗无症状性脑梗死的疗效及安全性。方法：选取我院2013年7月至2014年7月收治的无症状性脑梗死患者128例，随机分为联合用药组（n=98）和对照组（n=30），对照组口服阿司匹林100 mg/d，联合用药组在对照组的基础上加用阿托伐他汀，按其阿托伐他汀剂量不同分为A组32例（10 mg/d）、B组34例（20 mg/d）和C组32例（30 mg/d）3个亚组。治疗14 d后检查患者的血脂情况、血小板凝集功能和不良反应，0.5年后超声检测患者的斑块数量及稳定性。结果：用药前，组间血脂情况（CHOL、TG、LDL）、血小板凝集功能（CD62p、PAC-1、ET-1）、斑块数量和不稳定率比较差异无统计学意义；用药后，除HDL指标外，联合用药组患者上述指标均明显低于对照组（P＜0.05），且随着阿托伐他汀剂量的增加，上述指标逐渐减少；联合用药组患者HDL指标均明显高于对照组（P＜0.05），且随着阿托伐他汀剂量的增加，HDL逐渐增加（P＜0.05）；组间药物不良反应发生率比较差异无统计学意义。结论：阿托伐他汀联合阿司匹林治疗无症状性脑梗死的疗效满意，安全性高，且随着阿托伐他汀剂量的增加，血脂情况、血小板凝集功能和斑块稳定性呈逐渐改善趋势。
目的：探討不同劑量阿託伐他汀聯閤阿司匹林治療無癥狀性腦梗死的療效及安全性。方法：選取我院2013年7月至2014年7月收治的無癥狀性腦梗死患者128例，隨機分為聯閤用藥組（n=98）和對照組（n=30），對照組口服阿司匹林100 mg/d，聯閤用藥組在對照組的基礎上加用阿託伐他汀，按其阿託伐他汀劑量不同分為A組32例（10 mg/d）、B組34例（20 mg/d）和C組32例（30 mg/d）3箇亞組。治療14 d後檢查患者的血脂情況、血小闆凝集功能和不良反應，0.5年後超聲檢測患者的斑塊數量及穩定性。結果：用藥前，組間血脂情況（CHOL、TG、LDL）、血小闆凝集功能（CD62p、PAC-1、ET-1）、斑塊數量和不穩定率比較差異無統計學意義；用藥後，除HDL指標外，聯閤用藥組患者上述指標均明顯低于對照組（P＜0.05），且隨著阿託伐他汀劑量的增加，上述指標逐漸減少；聯閤用藥組患者HDL指標均明顯高于對照組（P＜0.05），且隨著阿託伐他汀劑量的增加，HDL逐漸增加（P＜0.05）；組間藥物不良反應髮生率比較差異無統計學意義。結論：阿託伐他汀聯閤阿司匹林治療無癥狀性腦梗死的療效滿意，安全性高，且隨著阿託伐他汀劑量的增加，血脂情況、血小闆凝集功能和斑塊穩定性呈逐漸改善趨勢。
목적：탐토불동제량아탁벌타정연합아사필림치료무증상성뇌경사적료효급안전성。방법：선취아원2013년7월지2014년7월수치적무증상성뇌경사환자128례，수궤분위연합용약조（n=98）화대조조（n=30），대조조구복아사필림100 mg/d，연합용약조재대조조적기출상가용아탁벌타정，안기아탁벌타정제량불동분위A조32례（10 mg/d）、B조34례（20 mg/d）화C조32례（30 mg/d）3개아조。치료14 d후검사환자적혈지정황、혈소판응집공능화불량반응，0.5년후초성검측환자적반괴수량급은정성。결과：용약전，조간혈지정황（CHOL、TG、LDL）、혈소판응집공능（CD62p、PAC-1、ET-1）、반괴수량화불은정솔비교차이무통계학의의；용약후，제HDL지표외，연합용약조환자상술지표균명현저우대조조（P＜0.05），차수착아탁벌타정제량적증가，상술지표축점감소；연합용약조환자HDL지표균명현고우대조조（P＜0.05），차수착아탁벌타정제량적증가，HDL축점증가（P＜0.05）；조간약물불량반응발생솔비교차이무통계학의의。결론：아탁벌타정연합아사필림치료무증상성뇌경사적료효만의，안전성고，차수착아탁벌타정제량적증가，혈지정황、혈소판응집공능화반괴은정성정축점개선추세。
Objective:To investigate the efifcacy and safety of different doses of atorvastatin combined with aspirin in the treatment of asymptomatic cerebral infarction.Methods:One hundred and twenty-eight patients with asymptomatic cerebral infarction were selected in our hospital from July, 2013 to July, 2014, and randomly divided into a combined treatment group (n=98) and a control group (n=30). Aspirin was orally administered at 100 mg/d in the control group, and in addition, atorvastatin was given to the combined treatment group. Subgroup A (10 mg/d,n=32), B (20 mg/d,n=34) and C (30 mg/d,n=32) were further divided according to the different doses. Blood lipids, platelet aggregation function and adverse reactions were checked 14 days after treatment and the number and stability of plaques were detected by B ultrasound after 6 months.Results: Comparison of blood lipids (CHOL, TG, lipid proifles LDL and HDL), platelet aggregation function (CD62p, PAC-1, ET-1), the number of and unstable rate of plaques between two groups showed no signiifcant difference before treatment while the above indexes except the HDL index were signiifcantly lower in the combined treatment group than in the control group (P<0.05) after treatment. The indexes decreased gradually with the increase of atorvastatin dose. HDL index was signiifcantly higher in the combined treatment group than in the control group (P<0.05), and HDL increased gradually with the increase of atorvastatin dose (P<0.05). The differences of adverse drug reaction between two groups had no statistically signiifcance.Conclusion:The curative effect of atorvastatin combined with aspirin is satisfactory for asymptomatic cerebral infarction with high safety, and blood lipid, plateletaggregation function and plaque stability are gradually improved with the increase of atorvastatin dose.
